The Comparison Between the Therapeutic Affect of Intravitreal Diclophenac and Triamcinolone in Persistent Uveitic Cystoids Macular Edema
试验速览
- 阶段
- 1 期
- 试验地点
- 1
研究概览
简要总结
Cystoids macular edema (CME) is one of the most common causes of low vision due to uveitis. The treatment for reducing the intra-ocular inflammation can decrease the macular edema. In some patients, CME persists even after inflammation control, and additional treatment is needed for better vision. Oral steroid, periocular and intravitreal Triamcinolone are the principles in treatment, but some complications like cataracts and increased ocular pressure have been seen. Diclophenac is a non-steroid anti-inflammatory drug that improves the vision and decreases the macular thickness by slowing down the prostaglandin E2 (PGE2) ending in vascular endothelial growth factor (VEGF) inhibition. In this study, the investigators are going to compare the therapeutic affect of intravitreal Diclophenac and Triamcinolone in persistent uveitic cystoids macular edema. Since diclophenac is a cheap and accessible drug in all curative centers it could be applied instead of Triamcinolone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •cystoids macular edema which is diagnosed by OCT and flurocein angiography
- •5/200 < Visual acuity < 20/50
- •resistance to routine treatment (oral treatment, periocular injection)
排除标准
- •history of retinal disease cause macular edema like diabetes
- •arterial occlusion
- •monocular patients
- •patients candidate for intra-ocular operation
- •history of glaucoma or ocular hypertension
- •any cataract that would interfere with OCT
研究组 & 干预措施
Diclophenac
干预措施: Diclophenac (Drug)
Triamcinolone
干预措施: Triamcinolone (Drug)
